News

A Stanford dermatologist explains how AI systems can reinforce racial bias in health care and underperform on skin cancer detection in darker skin.

PFAS found in cord blood linked to childhood gut inflammation and IBD risk; Elizabeth Spencer, MD, explains what it means for patients.

In RESOLVE-Lung, the anti-GM-CSF antibody namilumab did not reduce rescue events or improve lung function versus placebo in chronic pulmonary sarcoidosis.

Robert Wood, MD, of Johns Hopkins University explains what the July 31 exit means for peanut oral immunotherapy and omalizumab-assisted desensitization.

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Meagen McCusker, MD, discusses trusting instinct over rigid planning and why female physicians should lean on each other during career transitions.

Allergist Juanita Mora, MD, breaks down the ALA's COVID-19 prevention campaign — who needs a booster now, and how specialists can close the gap.

A prospective controlled study of 234 children finds food allergy raises ARFID-related picky eating and fear scores, but not appetite loss, Merve Karaca Şahin says.

Hematology in July 2026: FDA priority review for Agios' mitapivat in sickle cell disease, plus Orca-T's approval for GVHD-free survival.

Merck's sBLA seeks to extend clesrovimab-cfor (Enflonsia) coverage to children under 2 years at increased risk for severe RSV during their second season.

Stacey Rifkin-Zenenberg, DO, on gene therapy vs stem cell transplant and when to refer for sickle cell disease.

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

The mRNA-based vaccine wins full approval for adults aged 50 to 64 years and accelerated approval for adults aged ≥ 65 years following unanimous VRBPAC backing.

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Mandana Khalili, MD, discusses how baseline motivation predicted alcohol reduction in a stepped treatment trial for liver disease patients.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.

FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.

Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.

A JAMA study of nearly 25,000 vitiligo patients reveals major gaps in real-world treatment duration and consistency.

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

A study found children with and without food allergy screen positive for possible ARFID at similar rates, Daniela Ciciulla, APD, CEDC, says.

The FDA approved a 12-hour OTC combination of guaifenesin, dextromethorphan, and naproxen for cold and influenza symptom relief.

Tomashefski discusses where AATD diagnoses go missed and why APPs are positioned to close the gap.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

STOP-HS1 and STOP-HS2 data show povorcitinib nearly doubled treatment response rates versus placebo in moderate to severe HS.

Hepatology in July 2026: Odevixibat misses phase 3 primary endpoint, zabopegdutide shows early MASH benefit, plus a new Wilson disease NDA